



**JUBILANT**  
**LIFESCIENCES**

September 1, 2017

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 051

**Sub: Acquisition of Radiopharmacy business**

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication regarding acquisition of Radiopharmacy business.

This is for your information and records.

Thanking You,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Life Sciences Ltd.**

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

[www.jubl.com](http://www.jubl.com)

## **Jubilant completes acquisition of Radiopharmacy business of Triad**

***Noida (UP), India, Friday, September 1, 2017***

Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has successfully completed today the acquisition of the US radiopharmacy business of Triad Isotopes, Inc.

Speaking on the occasion, Mr. Shyam S Bhartia, Chairman, and Mr. Hari S Bhartia, Co-Chairman and Managing Director, said:

*“The acquisition adds significant scale to our niche Radiopharmaceutical business in the Specialty Pharma - Injectibles segment complementing our strategy of being a leading nuclear medicine player. Triad has an experienced management team, customer focus and strong relationships with GPOs in the United States, which allows us to directly serve customers through hospitals with high quality radiopharmaceutical products. We plan to expand the sales coverage to better and more optimally serve patients, physicians, imaging centers and hospitals, going forward.”*

This acquisition is funded through JPL’s internal accruals with no increase in debt for Jubilant Life Sciences Limited. Triad recorded revenues in excess of US\$ 225 Million in CY2016 with positive EBITDA and the acquisition is likely to be earnings accretive. Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies. The acquired radiopharmacies will continue to operate independently under the brand name of ‘Triad Isotopes’. The acquisition is a strategic fit to our niche nuclear medicine business and will provide Jubilant with direct access to hospital networks with ability to deliver more than 3 Million patient doses annually through approximately 1,700 customers. The company intends to maintain and expand Triad’s distribution network.

### **About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life



Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of over 6,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

**For more information, please contact:**

**For Investors**

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Ph: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*



**JUBILANT**  
*LIFESCIENCES*

## **Deal Announcement**

September 2017



# Disclaimer

This presentation (the "Presentation", or the "document") has been prepared by Jubilant Pharma Limited (the "Company" or "JPL") for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for use by the recipient only. The Presentation shall not, in whole or in part, be disclosed without prior written consent of the Company. This Presentation must not be copied, reproduced, distributed, or otherwise disclosed or passed on to others, in whole or in part, by any means, in any form under any circumstances whatsoever at any time hereafter. The recipient agrees to keep confidential any information contained herein and any other written or oral information otherwise made available in connection with the Company. In furnishing this document, neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, undertake any obligation to provide to the recipient (a) access to any additional information or to update this document, or (b) to correct any inaccuracies therein which may or may not become apparent.

This Presentation may contain statements about events and expectations that may be "forward-looking", including statements relating to future status, events, prospects or circumstances, including but not limited to statements about plans and objectives, outlook, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from these forward-looking statements due to number of risks and uncertainties, including future changes or developments in the Company's business, its competitive environment, its ability to implement its strategies and initiatives, respond to industry changes and the political, economic, regulatory and social conditions in India. The Company may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

JPL's statements related to the proposed acquisition of the radiopharmacy assets of Triad Isotopes Inc. contain "forward-looking" statements, including statements regarding expected benefits of the acquisition. Actual results could differ materially from those projected or forecast in the forward-looking statements. Factors that could cause actual results to differ materially may include the following- the parties may be unable to achieve the anticipated benefits of the transaction; revenues following the transaction may be lower than expected; operating costs, customer loss, and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; completing the acquisition may distract the Company's management from other important matters. The recipients are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

Certain statements in this communication constitute "forward-looking" statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by words such as "anticipate," "believe," "intend," "estimate," "expect," "see," "continue," "could," "can," "may," "will," "likely," "depend," "should," "would," "plan," "predict," "target," and similar expressions, and may include references to assumptions and relate to Triad Isotopes Inc. future prospects, developments and business strategies. Except for the historical information contained herein, the matters discussed in this communication are forward-looking statements that involve risks and uncertainties that may cause Triad Isotopes Inc.'s actual results to be materially different from such forward-looking statements and could materially adversely affect its business, financial condition, operating results and cash flows. These risks and uncertainties include the occurrence of any event, change or other circumstances; potential disruption of management's attention from Triad Isotopes Inc.'s ongoing business operations due to the Acquisition; the effect of the announcement of the Acquisition on the ability of Triad Isotopes Inc. to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does.

This Presentation does not constitute a prospectus, offering circular or offering memorandum or an offer invitation or a solicitation of any offer to purchase or sell, any securities of the Company, and should not be considered or construed in any manner whatsoever as a recommendation that any person should subscribe for or purchase any of Company's securities. None of the projections, expectations, estimates or prospects in this Presentation should be construed as a forecast implying any indicative assurance or guarantee of future performance, nor that the assumptions on which such future projections, expectations, estimates, or prospects have been prepared are complete or comprehensive.

This Presentation utilizes information which has not been independently verified (including by opinion, anecdote and speculation) and which has been sourced from a variety of public sources and third parties. Neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, makes any representation or warranty (expressly or impliedly) as to the accuracy, adequacy or completeness of this document or its contents or of any other oral or written information furnished or made available. The Company disclaim to the extent possible by law, all responsibility in relation to this Presentation.


This Presentation, is not a recommendation to invest, is not an investment advice, and, is prepared to provide background information for investors in relation to the Company. This Presentation does not purport to contain all information investors may require to evaluate an investment in the Company. In preparing the Presentation, the Company have not taken into account the particular investment objectives, financial situation or particular needs of investors. Before making an investment decision, an investor should independently consider whether an investment in the Company is appropriate in light of its particular investment needs, objectives and financial circumstances. An investor should conduct its own independent investigations, due diligence and analysis of the potential benefits and risks of any investment in the Company. An investor should seek professional advice, including tax advice before making an investment decision.

This Presentation does not constitute or form a part of any offer to sell, offer to purchase, or a solicitation to sell or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction. No securities of or relating to the Company referred to herein have been, and will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of the United States or any other jurisdiction and no such securities may be offered or sold in the United States absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and the rules and regulations thereunder. No public offering of securities will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. Any offer of such securities will be made by means of an offering document that will contain detailed information about the Company and its subsidiaries, the securities, as well as the Company's financial statements.

This Presentation may not be taken or transmitted into the United States, Canada or Japan and are not for distribution, directly or indirectly, in or into the United States, Canada or Japan. The distribution of this Presentation in or from certain other jurisdictions may also be restricted or prohibited by law. Recipients are required to inform themselves of, and comply with, all restrictions or prohibitions in relevant jurisdictions. Neither the Company nor any other person shall have any liability to any person in relation to the distribution or possession of this document or copies thereof in or from any jurisdiction where the distribution of such a document is prohibited or requires special authorization or any regulatory consent or approval. By accepting this document the recipient has agreed, upon request, to return promptly all material received from the Company without retaining any copies.

By accepting this Presentation, the recipient agrees that this Presentation is strictly confidential and shall not be copied, published, distributed or transmitted to any person, in whole or in part, by any means, in any form under any circumstances whatsoever and that the recipient has further agreed, upon request, to return promptly all material received from the Company without retaining any copies. The recipient further represents and warrants that it is lawfully able to receive this Presentation under the laws of the jurisdiction in which it is located and / or any other applicable laws, and that it will not reproduce, publish, disclose, redistribute or transmit this Presentation.


# Overview of the deal



- **Jubilant Pharma Limited (JPL)**, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has **completed the acquisition of the US radiopharmacy business of Triad Isotopes, Inc.**
- The acquisition is a strong **strategic fit** with our niche radiopharma business and will help us better **directly serve healthcare providers and their patients** with high-quality radiopharma products
- This acquisition is **funded through JPL's internal accruals** with no increase in debt for Jubilant Life Sciences Limited.
- The acquired radio-pharmacies will continue to operate independently under the brand name of **'Triad Isotopes'**

# About the target: Triad Isotopes is the second largest player in the US radio-pharmacies market

Triad Isotopes has the second largest network of radio-pharmacies in the US



**US\$225M+ revenue<sup>1</sup>** with positive EBITDA



**52 Radiopharmacies** spread across **22 states**



**3 Cyclotrons** serve PET customers



**700+** employees



**3 million+ doses delivered annually**



**1,700+ customers** across National GPOs, Regional Networks, local hospitals and physician groups



**Strong relationships** with all major national GPOs


**Strong management team, customer focus and proven past partnerships with global radio-pharma majors sets Triad apart from competition**

(1) CY16  
Note: All data as of Dec 2016

# The acquisition will add significant scale to the radio-pharma business of JPL



Revenue: ~US\$ 460M (FY17)



Revenue: ~US\$ 225M (CY16)

*JPL's radiopharmaceutical business specializes in lung, thyroid, bone and cardiac imaging, as well as thyroid disease therapies*

*Strong portfolio of niche and differentiated products including some 505(b)(2) filings*

*Broad pharmacy network of 50+ pharmacies spread across 22 states in US*

*Strong customer relationships with 1,700+ hospitals as well as major national GPOs*

## Post-acquisition\*

- The Specialty Pharmaceuticals – Injectables business will contribute ~US\$450M (~70%) of the total JPL revenue of ~US\$650M

\*On Annualized basis

# ...allowing for better sales coverage, channel access, deeper customer understanding and stronger R&D efforts

1

Increased sales reach, frequency and coverage



Higher hospital coverage for Triad and strong relationships with nuclear medicine professionals

2


Superior end-customer access and service



Ability to directly serve 1,700+ end customers with high quality products through Triad's network of 50+ pharmacies

3

Access to channel for recently approved product Ruby-Fill



Access to channel to facilitate go-to-market for Ruby-Fill

4

Stronger R&D efforts driven by deep customer understanding



Focused product development and greater success of new products driven by deep understanding of patient needs

5

Market expertise to maintain & expand Triad's distribution network



**JUBILANT**  
*LIFESCIENCES*

**Thank You**

